Skip to main content
Erschienen in: International Ophthalmology 11/2020

30.06.2020 | Original Paper

Optical coherence tomography angiography analysis of fabry disease

verfasst von: Ayse Idil Cakmak, Eray Atalay, Veysel Cankurtaran, Erdoğan Yaşar, Faruk Hilmi Turgut

Erschienen in: International Ophthalmology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Fabry disease (FD) is characterized by a deficiency in α-galactosidase A activity that leads to the cumulative deposition of unmetabolized glycosphingolipids within organs, including the vascular endothelium and the eyes. The purpose of this study was to assess the effects of FD on the retinal microvasculature, foveal avascular zone (FAZ), macular thickness and retinal nerve fiber layer (RNFL) using optical coherence tomography angiography (OCT-A).

Methods

Twenty-five patients (14 female and 11 male; mean age 33.16 ± 11.44) with genetically verified FD were compared with 37 age- and sex-matched healthy controls (mean age 32.36 ± 15.54). The vessel density (VD) values of the superficial and deep capillary plexuses (SCP and DCP), the area of the FAZ, the density of radial peripapillary capillaries (RPC), the macular thickness and the retinal nerve fiber layer thickness were measured by OCT-A examination.

Results

The patients showed significantly lower VD values than controls in the foveal regions of both SCP and the DCP (21.15 ± 5.56 vs. 23.79 ± 4.64 (p = 0.048), 37.92 ± 6.78 vs. 41.11 ± 5.59 (p = 0.048), respectively). The FAZ was significantly larger in the FD group than in the control group (0.3 ± 0.1 vs. 0.24 ± 0.08 (p = 0.011)). No significant difference was identified in measurements of RPC density, peripapillary RNFL thickness or macular thickness between the two groups (p > 0.05 for all).

Conclusion

Decreased VD and an enlarged foveal avascular area suggest possible changes in the retinal microvasculature of patients with FD. OCT-A can serve as a useful, noninvasive, quantitative tool for diagnosing FD and monitoring its progression.
Literatur
2.
Zurück zum Zitat Germain DP (2002) Fabry’s disease (alpha-galactosidase-A deficiency): recent therapeutic innovations. J Soc Biol 196(2):183–190PubMedCrossRef Germain DP (2002) Fabry’s disease (alpha-galactosidase-A deficiency): recent therapeutic innovations. J Soc Biol 196(2):183–190PubMedCrossRef
3.
Zurück zum Zitat Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 105(1–2):151–156PubMedCrossRef Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 105(1–2):151–156PubMedCrossRef
4.
Zurück zum Zitat Spada M, Pagliardini S, Yasuda M, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedPubMedCentralCrossRef Spada M, Pagliardini S, Yasuda M, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT, Fabry Outcome Survey İnvestigators (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRef Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT, Fabry Outcome Survey İnvestigators (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRef
6.
Zurück zum Zitat Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53(4):416–423PubMedCrossRef Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53(4):416–423PubMedCrossRef
7.
Zurück zum Zitat Bitirgen G, Turkmen K, Malik RA, Ozkagnici A, Zengin N (2018) Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease. Sci Rep 8(1):12244PubMedPubMedCentralCrossRef Bitirgen G, Turkmen K, Malik RA, Ozkagnici A, Zengin N (2018) Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease. Sci Rep 8(1):12244PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Sodi A, Ioannidis A, Mehta A, Davey C, Beck M, Pitz S (2007) Ocular manifestations of Fabry disease: data from the Fabry Outcome Survey. Br J Ophthalmol 91(2):210–214PubMedCrossRef Sodi A, Ioannidis A, Mehta A, Davey C, Beck M, Pitz S (2007) Ocular manifestations of Fabry disease: data from the Fabry Outcome Survey. Br J Ophthalmol 91(2):210–214PubMedCrossRef
9.
Zurück zum Zitat Morrier AM, Minteer J, Tyszko R, McCann R, Clarke MV, Browning MF (2010) Ocular manifestations of Fabry disease within in a single kindred. Optometry 81(9):437–449CrossRef Morrier AM, Minteer J, Tyszko R, McCann R, Clarke MV, Browning MF (2010) Ocular manifestations of Fabry disease within in a single kindred. Optometry 81(9):437–449CrossRef
11.
Zurück zum Zitat Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry’s disease. Arch Ophthalmol 97(4):671–676PubMedCrossRef Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry’s disease. Arch Ophthalmol 97(4):671–676PubMedCrossRef
12.
Zurück zum Zitat Franceschetti AT (1976) Fabry disease: ocular manifestations. Birth Defects Orig Artic Ser 12(3):195–208PubMed Franceschetti AT (1976) Fabry disease: ocular manifestations. Birth Defects Orig Artic Ser 12(3):195–208PubMed
13.
Zurück zum Zitat Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol 33(2):164–168PubMedCrossRef Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol 33(2):164–168PubMedCrossRef
14.
Zurück zum Zitat Libert J, Toussaint D (1982) Tortuosities of retinal and conjunctival vessels storage diseases. Birth Defects Orig Artic Ser 18(6):347–358PubMed Libert J, Toussaint D (1982) Tortuosities of retinal and conjunctival vessels storage diseases. Birth Defects Orig Artic Ser 18(6):347–358PubMed
15.
Zurück zum Zitat Sivley MD (2013) Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci 90(2):e63–e78PubMedCrossRef Sivley MD (2013) Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci 90(2):e63–e78PubMedCrossRef
16.
Zurück zum Zitat Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96(1):122–127PubMedCrossRef Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96(1):122–127PubMedCrossRef
17.
Zurück zum Zitat Huang D, Jia Y, Gao SS, Lumbroso B, Rispoli M (2016) Optical coherence tomography angiography using the optovue device. Dev Ophthalmol 56:6–12PubMedCrossRef Huang D, Jia Y, Gao SS, Lumbroso B, Rispoli M (2016) Optical coherence tomography angiography using the optovue device. Dev Ophthalmol 56:6–12PubMedCrossRef
18.
Zurück zum Zitat Lavia C, Bonnin S, Maule M, Erginay A, Tadayoni R, Gaudric A (2019) Vessel density of superficial, ıntermediate, and deep capillary plexuses using optical coherence tomography angiography. Retina 39(2):247–258PubMedCrossRef Lavia C, Bonnin S, Maule M, Erginay A, Tadayoni R, Gaudric A (2019) Vessel density of superficial, ıntermediate, and deep capillary plexuses using optical coherence tomography angiography. Retina 39(2):247–258PubMedCrossRef
19.
Zurück zum Zitat Mo S, Phillips E, Krawitz BD, Garg R, Salim S, Geyman LS et al (2017) Visualization of radial peripapillary capillaries using optical coherence tomography angiography: the effect of ımage averaging. PLoS ONE 12(1):e0169385PubMedPubMedCentralCrossRef Mo S, Phillips E, Krawitz BD, Garg R, Salim S, Geyman LS et al (2017) Visualization of radial peripapillary capillaries using optical coherence tomography angiography: the effect of ımage averaging. PLoS ONE 12(1):e0169385PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251(5):564–570PubMedCrossRef Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251(5):564–570PubMedCrossRef
21.
Zurück zum Zitat Kolodny EH, Pastores GM (2002) Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 13(2):S150–S153PubMedCrossRef Kolodny EH, Pastores GM (2002) Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 13(2):S150–S153PubMedCrossRef
22.
Zurück zum Zitat Desnick RJ, Ioannou YA, Eng CM (2001) Alpha-galactosidase A deficiency: Fabry’s disease. In: Scriever CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and molecular bases of ınherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774 Desnick RJ, Ioannou YA, Eng CM (2001) Alpha-galactosidase A deficiency: Fabry’s disease. In: Scriever CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and molecular bases of ınherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774
23.
Zurück zum Zitat Utsumi K, Ueda K, Watanabe M, Sakamaki M, Arii K, Yamazaki M, Komaba Y, Katsura K, Iino Y, Katayama Y (2009) Thrombosis in Japanese patients with Fabry disease. J Neurol Sci 283(1–2):83–85PubMedCrossRef Utsumi K, Ueda K, Watanabe M, Sakamaki M, Arii K, Yamazaki M, Komaba Y, Katsura K, Iino Y, Katayama Y (2009) Thrombosis in Japanese patients with Fabry disease. J Neurol Sci 283(1–2):83–85PubMedCrossRef
24.
Zurück zum Zitat Sher NA, Reiff W, Letson RD, Desnick RJ (1978) Central retinal artery occlusion complicating Fabry’s disease. Arch Ophthalmol 96(5):815–817PubMedCrossRef Sher NA, Reiff W, Letson RD, Desnick RJ (1978) Central retinal artery occlusion complicating Fabry’s disease. Arch Ophthalmol 96(5):815–817PubMedCrossRef
25.
Zurück zum Zitat Ersoz MG, Ture G (2018) Cilioretinal artery occlusion and anterior ischemic optic neuropathy as the initial presentation in a child female carrier of Fabry disease. Int Ophthalmol 38(2):771–773PubMedCrossRef Ersoz MG, Ture G (2018) Cilioretinal artery occlusion and anterior ischemic optic neuropathy as the initial presentation in a child female carrier of Fabry disease. Int Ophthalmol 38(2):771–773PubMedCrossRef
26.
Zurück zum Zitat Abe H, Sakai T, Sawaguchi S, Hasegawa S, Takagi M, Yoshizawa T, Usui T, Horikawa Y (1992) Ischemic optic neuropathy in a female carrier with Fabry’s disease. Ophthalmologica 205:83–88PubMedCrossRef Abe H, Sakai T, Sawaguchi S, Hasegawa S, Takagi M, Yoshizawa T, Usui T, Horikawa Y (1992) Ischemic optic neuropathy in a female carrier with Fabry’s disease. Ophthalmologica 205:83–88PubMedCrossRef
27.
Zurück zum Zitat Pitz S, Grube-Einwald K, Renieri G, Reinke J (2009) Subclinical optic neuropathy in Fabry disease. Ophthalmic Genet 30(4):165–171PubMedCrossRef Pitz S, Grube-Einwald K, Renieri G, Reinke J (2009) Subclinical optic neuropathy in Fabry disease. Ophthalmic Genet 30(4):165–171PubMedCrossRef
28.
Zurück zum Zitat Cennamo G, Di Maio LG, Montorio D, Tranfa F, Russo C, Pontillo G, Cocozza S, Esposito R, Di Risi T, Imbriaco M, Spinelli L, Riccio E, Pisani A (2019) Optical coherence tomography angiography findings in Fabry disease. J Clin Med 8:528PubMedCentralCrossRef Cennamo G, Di Maio LG, Montorio D, Tranfa F, Russo C, Pontillo G, Cocozza S, Esposito R, Di Risi T, Imbriaco M, Spinelli L, Riccio E, Pisani A (2019) Optical coherence tomography angiography findings in Fabry disease. J Clin Med 8:528PubMedCentralCrossRef
29.
Zurück zum Zitat Baur J, Al-Sheikh M, Barthelmes D, Nowak A, Böni C, Zweifel AS (2018) Optical Coherence Tomography Angiography findings in patients with Fabry’s disease. Investig Ophthalmol Vis Sci 59:4249CrossRef Baur J, Al-Sheikh M, Barthelmes D, Nowak A, Böni C, Zweifel AS (2018) Optical Coherence Tomography Angiography findings in patients with Fabry’s disease. Investig Ophthalmol Vis Sci 59:4249CrossRef
30.
Zurück zum Zitat Finocchio L, Sodi A, Bacherini D et al (2018) Optical coherence tomography angiography in Fabry disease. Investig Ophthalmol Vis Sci 59:2838 Finocchio L, Sodi A, Bacherini D et al (2018) Optical coherence tomography angiography in Fabry disease. Investig Ophthalmol Vis Sci 59:2838
31.
Zurück zum Zitat Utsumi K, Yamamoto N, Kase R, Takata T, Okumiya T, Saito H, Suzuki T, Uyama E, Sakuraba H (1997) High incidence of thrombosis in Fabry’s disease. Intern Med 36(5):327–329PubMedCrossRef Utsumi K, Yamamoto N, Kase R, Takata T, Okumiya T, Saito H, Suzuki T, Uyama E, Sakuraba H (1997) High incidence of thrombosis in Fabry’s disease. Intern Med 36(5):327–329PubMedCrossRef
32.
Zurück zum Zitat San Román I, Rodríguez ME, Caporossi O, Zoppetti C, Sodi A, Mecocci A, López D, Rodríguez B, Gimeno JR (2017) Computer assisted retinal vessel tortuosity evaluation in novel mutation Fabry disease: towards new prognostic markers. Retina 37(3):592–603PubMedCrossRef San Román I, Rodríguez ME, Caporossi O, Zoppetti C, Sodi A, Mecocci A, López D, Rodríguez B, Gimeno JR (2017) Computer assisted retinal vessel tortuosity evaluation in novel mutation Fabry disease: towards new prognostic markers. Retina 37(3):592–603PubMedCrossRef
33.
Zurück zum Zitat Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, Beck M, Gal A (2015) Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE 10(3):e0120814PubMedPubMedCentralCrossRef Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, Beck M, Gal A (2015) Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE 10(3):e0120814PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Orssaud C, Dufier J, Germain D (2003) Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 24(3):129–139PubMedCrossRef Orssaud C, Dufier J, Germain D (2003) Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 24(3):129–139PubMedCrossRef
35.
Zurück zum Zitat Liasis A, Ioannidis A, Thompson D, Davey C, Nischal K (2006) Visual electrophysiology in patients with Anderson-Fabry disease. Acta Paediatr Suppl 451:119 Liasis A, Ioannidis A, Thompson D, Davey C, Nischal K (2006) Visual electrophysiology in patients with Anderson-Fabry disease. Acta Paediatr Suppl 451:119
36.
Zurück zum Zitat Hufendiek K, Kaufeld J, Volkmann I, Brockmann D, Awe M, Kromer R, Hufendiek K, Junker B, Framme C (2018) Density of the retinal blood flow and thickness mapping by spectralis OCT in patients with Fabry disease. Investig Ophthalmol Vis Sci 59:5460 Hufendiek K, Kaufeld J, Volkmann I, Brockmann D, Awe M, Kromer R, Hufendiek K, Junker B, Framme C (2018) Density of the retinal blood flow and thickness mapping by spectralis OCT in patients with Fabry disease. Investig Ophthalmol Vis Sci 59:5460
37.
Zurück zum Zitat Minnella AM, Barbano L, Verrecchia E, Martelli F, Pagliei V, Gambini G et al (2019) Macular impairment in Fabry disease: a morphofunctional assessment by sweptsource OCT angiography and focal electroretinography. Invest Ophthalmol Vis Sci 60:2667–2675PubMedCrossRef Minnella AM, Barbano L, Verrecchia E, Martelli F, Pagliei V, Gambini G et al (2019) Macular impairment in Fabry disease: a morphofunctional assessment by sweptsource OCT angiography and focal electroretinography. Invest Ophthalmol Vis Sci 60:2667–2675PubMedCrossRef
Metadaten
Titel
Optical coherence tomography angiography analysis of fabry disease
verfasst von
Ayse Idil Cakmak
Eray Atalay
Veysel Cankurtaran
Erdoğan Yaşar
Faruk Hilmi Turgut
Publikationsdatum
30.06.2020
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 11/2020
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-020-01486-2

Weitere Artikel der Ausgabe 11/2020

International Ophthalmology 11/2020 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.